Condition: Heart Failure

The purpose of this phase 3 study is to evaluate the effect of finerenone compared to placebo in the reduction of cardiovascular death and total Heart Failure events, including HF hospitalization and urgent visits for HF in patients suffering from HF with an ejection fraction greater than or equal to 40%.

Location(s): St. Augustine

Condition: Heart Failure